Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC (RE-ARRANGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02835924
Recruitment Status : Active, not recruiting
First Posted : July 18, 2016
Last Update Posted : April 11, 2019
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Brief Summary:
The purpose of this study is to assess the safety and tolerability of different dose-escalation approaches of regorafenib in mCRC patients.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: Regorafenib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 299 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Study Comparing Different Dose Approaches of Induction Treatment (First Cycle) of Regorafenib in Metastatic Colorectal Cancer (mCRC) Patients
Actual Study Start Date : July 2016
Actual Primary Completion Date : September 2018
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Regorafenib

Arm Intervention/treatment
Active Comparator: Arm A
160 mg/day 3w on/1w off
Drug: Regorafenib
Experimental: Arm B
120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
Drug: Regorafenib
Experimental: Arm C
160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
Drug: Regorafenib



Primary Outcome Measures :
  1. Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria. [ Time Frame: 30 months ]

Secondary Outcome Measures :
  1. Percentage of total administrated dose over the planned dose accomplished in each arm. [ Time Frame: 30 months ]
  2. Dose intensity during the whole treatment. [ Time Frame: 30 months ]
  3. Dose intensity during first two cycles. [ Time Frame: 2 months ]
  4. Disease control rate (DCR) [ Time Frame: 30 months ]
  5. Progression-free survival (PFS) [ Time Frame: 30 months ]
  6. Time to treatment failure (TTF) [ Time Frame: 30 months ]
  7. Overall survival (OS) [ Time Frame: 30 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent (IC) obtained before any study specific procedures. Subjects must be able to understand and willing to sign a written informed consent.
  2. Male or female subjects 18 years of age.
  3. Life expectancy of at least 3 months.
  4. Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
  5. Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion following RECIST criteria v 1.1.
  6. Subjects with metastatic colorectal cancer (Stage IV).
  7. Progression during or within 3 months following the last administration of approved standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF and an anti-EGFR (if RAS WT)
  8. Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy
  9. Subjects who progress more than 6 months after completion of oxaliplatin containing adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible. Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study
  10. ECOG Performance Status of 0 or 1(within 14 days prior to the initiation of study treatment)
  11. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements:

    • Total bilirubin =1.5 x the upper limit of normal (ULN).
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN (5 x ULN for subjects with liver involvement of their cancer).
    • Alkaline phosphatase limit = 2.5 x ULN (5 x ULN for subjects with liver and/or bone involvement of their cancer).
    • Lipase = 1.5 x the ULN.
    • Serum creatinine 1.5 x the ULN or = 30 mL/min as calculated using the Cockcroft-Gault equation.
    • Platelet count >100000/mm3, hemoglobin >9 g/dL, absolute neutrophil count (ANC) >1500/mm3.
    • International normalized ratio (INR)/ Partial thromboplastin time (PTT) 1.5 x ULN. (Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard.
    • Blood transfusion to meet the inclusion criteria will not be allowed.
  12. Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last study drug administration. The investigator or a designated associate is requested to advise the subject on how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care. Women of childbearing potential must have a blood or urine pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatment.

Exclusion Criteria:

  1. Prior treatment with regorafenib.
  2. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug
  3. Pregnant or breast-feeding subjects:
  4. Congestive heart failure = New York Heart Association (NYHA) class 2.
  5. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months).
  6. Myocardial infarction less than 6 months before start of study drug.
  7. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
  8. Uncontrolled hypertension. (Systolic blood pressure > 140 mmHg or diastolic pressure >90 mmHg despite optimal medical management).
  9. Arterial or venous thromboembolism within 6 months prior to randomization.
  10. Pleural effusion or ascites that causes respiratory compromise (CTCAE Grade 2 dyspnea).
  11. Ongoing infection > Grade 2 CTCAE v. 4.0.
  12. Known history of human immunodeficiency virus (HIV) infection.
  13. Known history of active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy.
  14. Subjects with seizure disorder requiring medication.
  15. History of organ allograft.
  16. Subjects with evidence or history of any bleeding diathesis, irrespective of severity.
  17. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of study medication.
  18. Non-healing wound, ulcer, or bone fracture.
  19. Renal failure requiring hemo-or peritoneal dialysis.
  20. Dehydration CTCAE v. 4.0 Grade = 1.
  21. Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results.
  22. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation.
  23. Any illness or medical conditions that are unstable or could jeopardize the safety of the subject and his/her compliance in the study.
  24. Interstitial lung disease with ongoing signs and symptoms
  25. Persistent proteinuria of CTCAE Grade 3 (>3.5g/24 hours).
  26. Subjects unable to swallow oral medications.
  27. Any malabsorption condition.
  28. Unresolved toxicity higher than CTCAE (v. 4.0) > Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neurotoxicity > Grade 2.
  29. Subjects treated with strong CYP3A4 inhibitors or inducers (refer to appendix 8 and to section 6.3.8. Prohibited concomitant medication).
  30. Subjects receiving G-CSF within 3 weeks prior to signing the ICF
  31. Concomitant participation or participation within the last 30 days in another clinical trial
  32. Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 weeks (or within 6 weeks for mitomycin C) before starting to receive study medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02835924


Locations
Layout table for location information
Spain
Spanish Cooperative Group for the Treatment of Digestive Tumors
Madrid, Spain, 28007
Sponsors and Collaborators
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Bayer
Investigators
Layout table for investigator information
Study Chair: Guillem Argiles Hospital Universitary Vall d'Hebron
Study Chair: Josep Mª Tabernero, MD-PhD Hospital Universitary Vall d'Hebron

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
ClinicalTrials.gov Identifier: NCT02835924     History of Changes
Other Study ID Numbers: TTD-16-01
First Posted: July 18, 2016    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD):
regorafenib
metastatic colorectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases